Should the treatment of advanced lepidic adenocarcinoma be adapted to the pathological subtype?

Affiliations

Free article

Editorial

Marianne Paesmans. Eur Respir J. 2015 Nov.

Free article

. 2015 Nov;46(5):1259-61.

doi: 10.1183/13993003.01563-2015.

¹ Data Centre, Institut Jules Bordet, Centre des Tumeurs de l'Université Libre de Bruxelles, Brussels, Belgium marianne.paesmans@bordet.be.

No abstract available

Comment in

Sensitivity to chemotherapy/tyrosine kinase inhibitors of mucinous lepidic adenocarcinoma should be tested in a phase III trial?
Cadranel J, Wislez M, Langlais A, Morin F, Zalcman G. Cadranel J, et al. Eur Respir J. 2016 Jun;47(6):1890-1. doi: 10.1183/13993003.01936-2015. Eur Respir J. 2016. PMID: 27246084 No abstract available.

Erlotinib versus carboplatin and paclitaxel in advanced lepidic adenocarcinoma: IFCT-0504.
Cadranel J, Gervais R, Merle P, Moro-Sibilot D, Westeel V, Bigay-Game L, Quoix E, Friard S, Barlesi F, Lethrosne C, Moreau L, Monnet I, Salaun M, Oliviero G, Souquet PJ, Antoine M, Langlais A, Morin F, Wislez M, Zalcman G; Intergroupe Francophone de Cancérologie Thoracique (IFCT). Cadranel J, et al. Eur Respir J. 2015 Nov;46(5):1440-50. doi: 10.1183/13993003.02358-2014. Epub 2015 Sep 17. Eur Respir J. 2015. PMID: 26381515 Clinical Trial.